Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Fairmount Healthcare Fund II L.P. liquidated 1.75 million shares of Apogee Therapeutics common stock at $76.30 per share in January 2026, yielding approximately $133.5 million. This transaction took place near Apogee’s 52-week peak, against a backdrop of nearly doubling its stock value in the last year. Despite this strong price performance, some v…
The film 'Sinners' set a historic milestone by securing 16 Oscar nominations, surpassing previous records and positioning itself as a strong contender for Best Picture. The nominations highlight a broad spectrum of cinematic genres and showcase an Academy increasingly open to innovative storytelling. Key actors including Michael B. Jordan face nota…
Gerald L. Morgan, the CEO and Executive Vice Chairman of Texas Roadhouse Inc, sold 5,000 shares at $196 each on January 20, 2026, totaling $980,000. The sale took place close to the stock’s 52-week peak of $199.99, with shares stable at $191.25 currently. Texas Roadhouse maintains a robust financial stance, reflected in a 'GREAT' InvestingPro score…
Stitch Fix Chief Financial Officer David Aufderhaar sold 24,114 shares of Class A Common Stock on January 20, 2026, at $5.1264 per share, totaling $123,618. Despite the sale, Aufderhaar retains a substantial 1,251,862 shares. The company’s stock is currently slightly above the CFO’s sale price and is considered undervalued by InvestingPro’s Fair Va…
The U.S. dollar is set to experience its largest weekly decrease in a year, triggered by recent geopolitical developments including President Trump's statements on Greenland. Meanwhile, the Japanese yen remains under pressure as investors await the Bank of Japan's policy decision. Market participants are closely watching these dynamics amid concern…
ByteDance, TikTok's parent company, has reached an agreement to establish a U.S.-based joint venture with majority American ownership to address government concerns and avoid a ban on the widely used social media platform. The move follows years of scrutiny over national security risks associated with TikTok, which boasts over 200 million users in …
GigaCloud Technology Inc's CEO Wu Lei and related entities executed a series of share sales totaling approximately $892,140 between January 20 and 22, 2026. Despite these transactions, the company shows robust financial health, with strong quarterly earnings surpassing expectations and strategic moves including a recent acquisition. The sales were …
Kenneth Duda, President and CTO of Arista Networks, completed a substantial sale of nearly 30,000 shares and exercised stock options, amidst the company's rising share price and ongoing favorable analyst recommendations. Additional share sales by trusts linked to Duda highlight internal liquidity actions as the company prepares for its upcoming ear…
Elliot Dean Hoops, serving as General Counsel and Secretary for MP Materials Corp, finalized a stock sale valued at approximately $533,606, disposing of 7,823 shares at varied prices in late January 2026. This transaction adhered to a previously established Rule 10b5-1 trading schedule. Concurrently, MP Materials has reported important progress in …
Christopher Gibson, director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock in January 2026, coinciding with a stock conversion of Class B to Class A shares. Meanwhile, the company disclosed promising interim results from its Phase 1b/2 TUPELO trial assessing the investigational drug REC-4881, showing substantial reduction…
Jonathan Zalevsky, Chief Research and Development Officer at biopharmaceutical company Nektar Therapeutics, sold 3,867 company shares worth approximately $137,935 at an average price of $35.67 on January 20, 2026. This transaction follows recent mixed results from Nektar's Phase 2b REZOLVE-AA trial for alopecia areata, which narrowly missed its pri…
Campbell Bradley L., the President and CEO of Amicus Therapeutics, completed a sale of 75,000 shares on January 20, 2026, generating approximately $1.07 million. Alongside this, he exercised options to acquire an equal number of shares. This insider activity coincides with a strong market performance for Amicus shares and the announcement of an all…
EverCommerce Inc. CEO Eric Richard Remer completed two stock sale transactions in late January 2026, liquidating approximately $171,000 in shares through a structured trading plan. The company recently announced third-quarter 2025 results reflecting slight revenue gains yet received cautious analyst reactions, highlighting a balanced risk landscape…
Jay L. Schottenstein, serving as Executive Chairman and CEO of American Eagle Outfitters (NASDAQ:AEO), executed a series of stock sales totaling nearly $26.8 million by divesting 1,049,679 shares within a three-day period. Concurrently, the company has adjusted its fourth-quarter operating income forecast upward and announced a strategic global par…
In response to increasing global geopolitical tensions and soaring government debt, Bitwise and Proficio Capital Partners have introduced a novel exchange-traded fund (ETF) designed to offer investors diversified exposure to assets beyond traditional currencies. This ETF emphasizes precious metals such as gold, silver, platinum, and palladium along…
President Donald Trump voiced skepticism about a proposal from his chief economic adviser to permit individuals to withdraw money from their 401(k) retirement accounts to finance home down payments. Despite the administration's interest in expanding homeownership and making housing more affordable, Trump emphasized his preference for maintaining th…
John Alexander Kelly, CFO of Precision Biosciences Inc., sold over 15,000 shares at $4.03 each on January 21, 2026, amounting to just above $61,000. Concurrently, Kelly vested a substantial number of restricted stock units the previous day. Precision Biosciences continues to make progress in its gene editing programs and financial positioning amids…
Dario Scimeca, the General Counsel and Secretary of Precision BioSciences (NASDAQ:DTIL), executed the sale of 8,854 of the company’s common shares for a total of $35,681 on January 21, 2026. This transaction comes while the stock trades slightly above the sale price and amid an InvestingPro assessment rating the shares as overvalued. Concurrently, …
Precision Biosciences Inc's Chief Research Officer, Smith J. Jefferson, recently sold over 10,000 shares of the company's stock while concurrently acquiring a larger number of shares from vested Restricted Stock Units. The company continues to move forward with key gene editing clinical trials and maintains strong liquidity after a recent capital r…
U.S. stock futures held steady Thursday evening, stabilizing after a brief surge fueled by improving geopolitics around Greenland and enthusiasm for technology stocks, particularly those tied to artificial intelligence. Intel shares declined sharply after the chipmaker issued a cautious outlook for the upcoming quarter, overshadowing its better-tha…
Japanese Prime Minister Sanae Takaichi's call for an early general election on February 8 aims to secure public support for her aggressive reflation strategy, impacting bond yields and stirring debate on fiscal and monetary policy. Various political parties present contrasting approaches on taxation, fiscal discipline, and monetary policy, reflecti…
Mara Holdings CEO Frederick G. Thiel sold over 27,000 shares on January 20, 2026, netting approximately $297,000. The transaction was part of a pre-established trading plan, set against the backdrop of fluctuating cryptocurrency markets and varied analyst outlooks. Despite recent declines in Mara's stock tied to Bitcoin price weakness, the company’…
Abraham Ceesay, CEO of clinical-stage biotech firm Rapport Therapeutics, sold just over 10,900 shares valued at approximately $285,000 in two transactions under a pre-established trading plan. These dealings occur as the company expedites Phase 3 trials for its epilepsy drug RAP-219, earning favorable analyst responses and raising price targets for…
DraftKings Inc.'s Chief Legal Officer, Dodge R Stanton, recently undertook significant stock transactions involving both the sale of shares and the exercise of stock options. These actions took place against a backdrop of notable share price volatility, analyst optimism about the company’s potential profitability, and a fluctuating online sports be…
In January, British consumer confidence modestly strengthened to a level not seen since August 2024, as individuals expressed more optimism regarding their personal financial situations. Nonetheless, unease about the UK's overall economy remains pronounced, according to a recent GfK survey. The mixed sentiment reflects a focus on controllable perso…
